Calculate your body mass index (BMI)




Your BMI

Back to list

Asthmatic Volunteers 240729

Study Dates: 23/11/19 - 31/3/20

Trial Number



●  Asthma
●  Non-Childbearing Females


Up to: $4,820


Male, Female, Non-Smoker



Additional Information

    Part 2 of this study will recruit up to 78 non-smoking, male and female (of non-childbearing potential) patients with mild asthma between 18 and 65 years old.

    Cohort 2b

    • Admission: 11th January 2020
    • Discharge: 26th January 2020
    • Outpatient: 27th January 2020
    • Follow-up: 30th January 2020

    Cohort 2c

    • Admission: 18th January 2020
    • Discharger: 2nd February 2020
    • Outpatient visit : 3rd February 2020
    • Follow up : 6th February 2020

    Cohort 2d

      • Admission: 25th January 2020
      • Discharger: 9th February 2020
      • Outpatient visit : 10th February 2020
      • Follow up : 13th February 2020

Please call Recruitment on 01895 614 888 for upcoming screening dates.


We are currently recruiting Mild Asthmatics who are using the Blue sulbutamol inhaler (Ventolin), only.

The study involves a stay of 15 nights in our unit with two follow up visits. Total duration of the study is 18 days.

Start dates are flexible so please call us to see if we can work around your calander.

The main purpose of the study is to see how safe the Study Drug is and how well it is tolerated after dosing.

The study will also investigate:

• How the Study Drug is taken up, metabolised (chemically broken down), distributed through the body and excreted, this is called the pharmacokinetics (PK) of the Study Drug.

• How the body is affected by the Study Drug, this is called the pharmacodynamics (PD) of the Study Drug.

• Try to understand why different people respond differently to the same drug through DNA testing (please refer to the separate informed consent form for genetic testing).The sponsor is developing the study drug as a treatment for asthma. Asthma is a chronic disease of the airways that makes breathing difficult. The study drug works by preventing the formation of certain proteins by the immune system, which cause inflammation (swelling), and so reducing the symptoms of asthma.

This is a first time in human study.